Ovarian Cancer

Toon Van Gorp, MD, PhD, discusses key data with TUB-040 in platinum-resistant ovarian cancer and next steps for development.

The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.

Long-term data from the L-MOCA trial showed encouraging OS outcomes with olaparib maintenance in Asian patients with platinum-sensitive, relapsed ovarian cancer.

CHMP has recommended EU approval of senaparib for advanced ovarian cancer based on FLAMES data.

CHMP has recommended EU marketing authorization for relacorilant combined with nab-paclitaxel in platinum-resistant ovarian cancer.

Toon Van Gorp, MD, PhD, discusses NAPISTAR 1-01 trial design, safety findings, and efficacy across dose levels of TUB-040 in ovarian cancer.

Alexandra Leary, MD, PhD, discusses TEDOVA's design, the safety profile of OSE2101, and implications for maintenance in ovarian cancer.

ASCO's first living guideline backs platinum doublets and mirvetuximab soravtansine for FRα+, high-grade platinum-resistant ovarian cancer.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.

Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.

The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.

BI-1808 combined with pembrolizumab elicited a 24% confirmed overall response rate in heavily pretreated, platinum-resistant recurrent ovarian cancer.

PD-L1 IHC 22C3 pharmDx gained EU approval as a companion diagnostic for pembrolizumab in platinum-resistant epithelial ovarian cancer.

Top experts discuss the most important takeaways and data in ovarian and endometrial cancer to come out of this year’s ASCO annual meeting.

Sacituzumab govitecan produced an ORR of 35% in heavily pretreated platinum-resistant ovarian cancer in a phase 2 study.

The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Experts convened to discuss ADC sequencing strategies, biomarker testing infrastructure, and emerging data across cervical, ovarian, and endometrial cancers.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

The FDA accepted for review a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in LBCL, a BLA for ozekibart in chondrosarcoma, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Despite a higher response rate with the combination, the phase 2 MIROVA/AGO-OVAR 2.34 trial did not meet its primary PFS end point over chemotherapy.

External validation of a circulating immune protein signature model confirmed its prognostic value for OS in recurrent ovarian cancer.

ASCO 2026 highlights show dostarlimab may deliver curative potential in dMMR endometrial cancer, while novel ADCs and fasting reshape ovarian care.